BioAtla (BCAB) Competitors

$3.69 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$3.72 +0.04 (+0.95%)

As of 05/22/2026 04:32 PM Eastern

BCAB vs. SKYE, PLRZ, BCTX, BRNS, and SNSE

Should you buy BioAtla stock or one of its competitors? MarketBeat compares BioAtla with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BioAtla include Skye Bioscience (SKYE), Polyrizon (PLRZ), Briacell Therap (BCTX), Barinthus Biotherapeutics (BRNS), and Sensei Biotherapeutics (SNSE). These companies are all part of the "pharmaceutical products" industry.

How does BioAtla compare to Skye Bioscience?

Skye Bioscience (NASDAQ:SKYE) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, valuation and profitability.

Skye Bioscience has higher earnings, but lower revenue than BioAtla. Skye Bioscience is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Skye Bioscience	N/A	N/A	-$55.92M	-$1.44	N/A
BioAtla	$2M	3.06	-$59.61M	-$50.50	N/A

21.1% of Skye Bioscience shares are held by institutional investors. Comparatively, 77.2% of BioAtla shares are held by institutional investors. 6.2% of Skye Bioscience shares are held by company insiders. Comparatively, 11.8% of BioAtla shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Skye Bioscience had 9 more articles in the media than BioAtla. MarketBeat recorded 9 mentions for Skye Bioscience and 0 mentions for BioAtla. Skye Bioscience's average media sentiment score of 0.70 beat BioAtla's score of 0.00 indicating that Skye Bioscience is being referred to more favorably in the media.

Company	Overall Sentiment
Skye Bioscience	Positive
BioAtla	Neutral

BioAtla's return on equity of 0.00% beat Skye Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Skye Bioscience	N/A	-217.27%	-162.39%
BioAtla	N/A	N/A	-307.62%

Skye Bioscience currently has a consensus target price of $9.80, suggesting a potential upside of 1,081.72%. BioAtla has a consensus target price of $200.00, suggesting a potential upside of 5,320.05%. Given BioAtla's higher probable upside, analysts plainly believe BioAtla is more favorable than Skye Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Skye Bioscience	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57
BioAtla	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Skye Bioscience has a beta of 3.03, indicating that its share price is 203% more volatile than the broader market. Comparatively, BioAtla has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market.

Summary

Skye Bioscience beats BioAtla on 9 of the 15 factors compared between the two stocks.

How does BioAtla compare to Polyrizon?

BioAtla (NASDAQ:BCAB) and Polyrizon (NASDAQ:PLRZ) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, institutional ownership, risk, profitability, analyst recommendations and dividends.

In the previous week, BioAtla's average media sentiment score of 0.00 equaled Polyrizon'saverage media sentiment score.

Company	Overall Sentiment
BioAtla	Neutral
Polyrizon	Neutral

BioAtla currently has a consensus price target of $200.00, indicating a potential upside of 5,320.05%. Given BioAtla's stronger consensus rating and higher possible upside, analysts clearly believe BioAtla is more favorable than Polyrizon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAtla	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

BioAtla has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market. Comparatively, Polyrizon has a beta of -2.04, meaning that its share price is 304% less volatile than the broader market.

77.2% of BioAtla shares are owned by institutional investors. 11.8% of BioAtla shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
BioAtla	N/A	N/A	-307.62%
Polyrizon	N/A	N/A	N/A

Polyrizon has lower revenue, but higher earnings than BioAtla.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAtla	$2M	3.06	-$59.61M	-$50.50	N/A
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A

Summary

BioAtla beats Polyrizon on 7 of the 9 factors compared between the two stocks.

How does BioAtla compare to Briacell Therap?

Briacell Therap (NASDAQ:BCTX) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, analyst recommendations, institutional ownership and risk.

BioAtla's return on equity of 0.00% beat Briacell Therap's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Briacell Therap	N/A	-173.08%	-139.64%
BioAtla	N/A	N/A	-307.62%

Briacell Therap has a beta of 1.26, suggesting that its share price is 26% more volatile than the broader market. Comparatively, BioAtla has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market.

BioAtla has a consensus target price of $200.00, suggesting a potential upside of 5,320.05%. Given BioAtla's stronger consensus rating and higher possible upside, analysts clearly believe BioAtla is more favorable than Briacell Therap.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Briacell Therap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
BioAtla	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Briacell Therap had 1 more articles in the media than BioAtla. MarketBeat recorded 1 mentions for Briacell Therap and 0 mentions for BioAtla. Briacell Therap's average media sentiment score of 0.00 equaled BioAtla'saverage media sentiment score.

Company	Overall Sentiment
Briacell Therap	Neutral
BioAtla	Neutral

15.4% of Briacell Therap shares are held by institutional investors. Comparatively, 77.2% of BioAtla shares are held by institutional investors. 0.7% of Briacell Therap shares are held by company insiders. Comparatively, 11.8% of BioAtla shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Briacell Therap has higher earnings, but lower revenue than BioAtla. Briacell Therap is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Briacell Therap	N/A	N/A	-$26.31M	-$23.33	N/A
BioAtla	$2M	3.06	-$59.61M	-$50.50	N/A

Summary

BioAtla beats Briacell Therap on 8 of the 13 factors compared between the two stocks.

How does BioAtla compare to Barinthus Biotherapeutics?

Barinthus Biotherapeutics (NASDAQ:BRNS) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

BioAtla has lower revenue, but higher earnings than Barinthus Biotherapeutics. Barinthus Biotherapeutics is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Barinthus Biotherapeutics	$14.97M	1.89	-$66.43M	-$1.29	N/A
BioAtla	$2M	3.06	-$59.61M	-$50.50	N/A

25.2% of Barinthus Biotherapeutics shares are owned by institutional investors. Comparatively, 77.2% of BioAtla shares are owned by institutional investors. 10.7% of Barinthus Biotherapeutics shares are owned by company insiders. Comparatively, 11.8% of BioAtla shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

BioAtla's return on equity of 0.00% beat Barinthus Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Barinthus Biotherapeutics	N/A	-63.83%	-48.77%
BioAtla	N/A	N/A	-307.62%

Barinthus Biotherapeutics has a beta of -0.43, suggesting that its stock price is 143% less volatile than the broader market. Comparatively, BioAtla has a beta of 0.81, suggesting that its stock price is 19% less volatile than the broader market.

Barinthus Biotherapeutics presently has a consensus target price of $4.00, indicating a potential upside of 477.20%. BioAtla has a consensus target price of $200.00, indicating a potential upside of 5,320.05%. Given BioAtla's higher possible upside, analysts clearly believe BioAtla is more favorable than Barinthus Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Barinthus Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
BioAtla	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Barinthus Biotherapeutics had 1 more articles in the media than BioAtla. MarketBeat recorded 1 mentions for Barinthus Biotherapeutics and 0 mentions for BioAtla. Barinthus Biotherapeutics' average media sentiment score of 0.00 equaled BioAtla'saverage media sentiment score.

Company	Overall Sentiment
Barinthus Biotherapeutics	Neutral
BioAtla	Neutral

Summary

BioAtla beats Barinthus Biotherapeutics on 8 of the 12 factors compared between the two stocks.

How does BioAtla compare to Sensei Biotherapeutics?

Sensei Biotherapeutics (NASDAQ:SNSE) and BioAtla (NASDAQ:BCAB) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends and profitability.

Sensei Biotherapeutics presently has a consensus price target of $45.00, suggesting a potential upside of 152.95%. BioAtla has a consensus price target of $200.00, suggesting a potential upside of 5,320.05%. Given BioAtla's higher possible upside, analysts clearly believe BioAtla is more favorable than Sensei Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sensei Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
BioAtla	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

BioAtla's return on equity of 0.00% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sensei Biotherapeutics	N/A	-803.00%	-256.50%
BioAtla	N/A	N/A	-307.62%

Sensei Biotherapeutics has higher earnings, but lower revenue than BioAtla. Sensei Biotherapeutics is trading at a lower price-to-earnings ratio than BioAtla, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$142.72	N/A
BioAtla	$2M	3.06	-$59.61M	-$50.50	N/A

10.5% of Sensei Biotherapeutics shares are held by institutional investors. Comparatively, 77.2% of BioAtla shares are held by institutional investors. 23.2% of Sensei Biotherapeutics shares are held by insiders. Comparatively, 11.8% of BioAtla shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Sensei Biotherapeutics had 2 more articles in the media than BioAtla. MarketBeat recorded 2 mentions for Sensei Biotherapeutics and 0 mentions for BioAtla. Sensei Biotherapeutics' average media sentiment score of 0.00 equaled BioAtla'saverage media sentiment score.

Company	Overall Sentiment
Sensei Biotherapeutics	Neutral
BioAtla	Neutral

Sensei Biotherapeutics has a beta of -0.18, meaning that its stock price is 118% less volatile than the broader market. Comparatively, BioAtla has a beta of 0.81, meaning that its stock price is 19% less volatile than the broader market.

Summary

BioAtla beats Sensei Biotherapeutics on 7 of the 13 factors compared between the two stocks.

Get BioAtla News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BCAB vs. The Competition

Export

Metric	BioAtla	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.11M	$3.37B	$6.46B	$12.34B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	-0.07	18.74	21.00	25.66
Price / Sales	3.06	323.98	562.18	86.31
Price / Cash	N/A	125.17	43.49	56.67
Price / Book	-0.16	7.09	10.41	7.14
Net Income	-$59.61M	$24.45M	$3.57B	$335.98M
7 Day Performance	-4.65%	6.38%	6.40%	4.11%
1 Month Performance	-24.23%	2.43%	3.54%	2.52%
1 Year Performance	-81.08%	62.98%	34.14%	35.04%

BioAtla Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BCAB BioAtla	1.273 of 5 stars	$3.69 flat	$200.00 +5,320.1%	-81.1%	$6.11M	$2M	N/A	60
SKYE Skye Bioscience	2.8111 of 5 stars	$0.85 -3.5%	$9.80 +1,054.3%	-56.4%	$29.83M	N/A	N/A	11	Analyst Revision Gap Down
PLRZ Polyrizon	0.5864 of 5 stars	$15.82 -1.9%	N/A	+199.2%	$29.57M	N/A	N/A	N/A	Gap Down
BCTX Briacell Therap	0.197 of 5 stars	$4.04 -2.8%	N/A	-88.6%	$29.27M	N/A	N/A	8
BRNS Barinthus Biotherapeutics	2.2259 of 5 stars	$0.71 +3.4%	$4.00 +465.0%	+6.0%	$28.92M	N/A	N/A	107	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BCAB) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BioAtla (BCAB) Competitors

BCAB vs. SKYE, PLRZ, BCTX, BRNS, and SNSE

How does BioAtla compare to Skye Bioscience?

Summary

How does BioAtla compare to Polyrizon?

Summary

How does BioAtla compare to Briacell Therap?

Summary

How does BioAtla compare to Barinthus Biotherapeutics?

Summary

How does BioAtla compare to Sensei Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCAB vs. The Competition

BioAtla Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BioAtla (BCAB) Competitors

BCAB vs. SKYE, PLRZ, BCTX, BRNS, and SNSE

How does BioAtla compare to Skye Bioscience?

Which has stronger valuation & earnings, SKYE or BCAB?

Do institutionals & insiders believe in SKYE or BCAB?

Does the media prefer SKYE or BCAB?

Is SKYE or BCAB more profitable?

Do analysts prefer SKYE or BCAB?

Which has more risk & volatility, SKYE or BCAB?

Summary

How does BioAtla compare to Polyrizon?

Does the media favor BCAB or PLRZ?

Do analysts recommend BCAB or PLRZ?

Which has more volatility and risk, BCAB or PLRZ?

Do insiders & institutionals believe in BCAB or PLRZ?

Is BCAB or PLRZ more profitable?

Which has higher valuation & earnings, BCAB or PLRZ?

Summary

How does BioAtla compare to Briacell Therap?

Is BCTX or BCAB more profitable?

Which has more volatility & risk, BCTX or BCAB?

Do analysts recommend BCTX or BCAB?

Does the media prefer BCTX or BCAB?

Do insiders and institutionals hold more shares of BCTX or BCAB?

Which has higher valuation & earnings, BCTX or BCAB?

Summary

How does BioAtla compare to Barinthus Biotherapeutics?

Which has preferable valuation & earnings, BRNS or BCAB?

Do institutionals and insiders have more ownership in BRNS or BCAB?

Is BRNS or BCAB more profitable?

Which has more volatility and risk, BRNS or BCAB?

Do analysts recommend BRNS or BCAB?

Does the media prefer BRNS or BCAB?

Summary

How does BioAtla compare to Sensei Biotherapeutics?

Do analysts recommend SNSE or BCAB?

Is SNSE or BCAB more profitable?

Which has better valuation & earnings, SNSE or BCAB?

Do institutionals & insiders hold more shares of SNSE or BCAB?

Does the media prefer SNSE or BCAB?

Which has more volatility & risk, SNSE or BCAB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCAB vs. The Competition

BioAtla Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools